Huchembio Co. Ltd. has described signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of autoimmune diseases, atherosclerosis, inflammatory disorders, cancer, diabetic retinopathy, diabetes, osteoporosis and viral infections.
Researchers have compared the cellular responses driving allergic asthma to those in individuals with allergic rhinitis and conjunctivitis but no allergic response in the lungs. Asthma is “an umbrella term,” Josalyn Cho told BioWorld. But under that umbrella, the largest group of people are those whose asthma begins in childhood. And “those folks almost exclusively develop their asthma after they develop allergies.”
With much-awaited readouts from their broad oncology-focused collaboration due later this year, Arcus Biosciences Inc. and Gilead Sciences Inc. have decided to expand efforts into the inflammatory disease space via an early stage research agreement that could be worth as much as $1 billion. Terms include a $35 million up-front payment to Arcus, which is making its first move beyond oncology.
By analyzing a cohort of adolescents that developed myocarditis or pericarditis after vaccination against SARS-CoV-2 vaccination, researchers from Yale University School of Medicine were able to pinpoint the underlying mechanism as an overly active innate immune response to the vaccine that led to broad activation of T cells and natural killer (NK) cells. Myocarditis “has been seen in other vaccine contexts, though is most common after viral infection,” Carrie Lucas told reporters at a press conference announcing the findings.
Albatroz Therapeutics Pte Ltd. has secured $3 million in seed funding to develop therapeutic antibodies against a new target that degrades the extracellular matrix, a key contributor to cancer and arthritis.
Macrophages, a cell type involved in the inflammatory response, are also responsible for collagen deposition in lung and liver fibrosis. In a recently published study, researchers identified a subpopulation of profibrotic macrophages.
Vyne Therapeutics Inc. has selected a development candidate, VYN-202, for its oral BD2-selective bromodomain and extra-terminal (BET) inhibitor program for the treatment of immuno-inflammatory conditions.
RSS
